(Hypertension. 1999;33:559-564.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
Hyperglycemia and Angiotensin-Mediated Control of the Renal Circulation in Healthy Humans
From the Department of Medicine and Division of Endocrinology (S.Y.O., D.A.P., N.D.L.F., L.P., N.K.H.), and Department of Radiology (N.K.H.), Brigham and Women's Hospital and the Joslin Diabetes Center (L.M.B.L.), Harvard Medical School, Boston, Mass.
Correspondence to Suzette Y. Osei, MD, PhD, Brigham and Women's Hospital, Endocrine-Hypertension Division, 221 Longwood Ave, Boston, MA 02115. E-mail syosei{at}bics.bwh.harvard.edu
Abstract—Type 1 and type 2 diabetics have an enhanced renal vasodilator response to angiotensin-converting enzyme (ACE) inhibition despite suppressed plasma renin activity (PRA), indicating possible activation of the intrarenal renin angiotensin system. To investigate the role of hyperglycemia, we evaluated the renal hemodynamic response to ACE inhibition in 9 healthy subjects in high-salt balance after steady-state hyperglycemia (8.4±1 mmol/L) was achieved via intravenous glucose administration. Renal plasma flow (RPF) and glomerular filtration rate (GFR) responses to captopril and to angiotensin II (Ang II) were measured as paraminohippuric acid and inulin clearances. Hyperglycemia produced a significant increase in RPF of 117 mL · min-1 · 1.73 m-2 after 90 minutes but not GFR. Administration of captopril at a dose of 25 mg during glucose infusion led to an increase in RPF of 173±24 mL · min-1 · 1.73 m-2 (P<0.01) but did not significantly change RPF in the absence of hyperglycemia (7±21 mL · min-1 · 1.73 m-2). Captopril did not alter GFR in the presence or absence of hyperglycemia. Ang II infusion during hyperglycemia decreased RPF by 45±16 mL · min-1 · 1.73 m-2, and this was significantly enhanced by captopril (-98±26 mL · min-1 · 1.73 m-2, P<0.05). In contrast, there was no enhancement of the vasoconstrictor response to Ang II in the absence of hyperglycemia. PRA did not change with hyperglycemia. Enhancement of renal vasodilation during hyperglycemia by captopril without alteration of PRA suggests activation of the intrarenal renin angiotensin system.
Key Words: renal blood flow • glomerular filtration rate • hyperglycemia • sodium • renin
This article has been cited by other articles:
 |
|
 |
|
  B. Volkan-Salanci, S. Dagdelen, M. Alikasifoglu, T. Erbas, M. Hayran, and B. Erbas Impact of renin-angiotensin system polymorphisms on renal haemodynamic responsiveness to acute angiotensin-converting enzyme inhibition in type 2 diabetes mellitus Journal of Renin-Angiotensin-Aldosterone System, March 1, 2009; 10(1): 41 - 50. [Abstract] [PDF]
|
|
|
|
 |
|
 M. W. Brands, T. D. Bell, N. A. Rodriquez, P. Polavarapu, and D. Panteleyev Chronic glucose infusion causes sustained increases in tubular sodium reabsorption and renal blood flow in dogs Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2009; 296(2): R265 - R271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D Stevanovic, N. D. Fisher, C. M Lansang, K. D Freeman, and N. K Hollenberg Short- and long-term glycaemic control and the state of the renin system in type 1 diabetes mellitus Journal of Renin-Angiotensin-Aldosterone System, June 1, 2007; 8(2): 85 - 92. [Abstract] [PDF]
|
|
|
|
 |
|
 T. S. Perlstein, M. Gerhard-Herman, N. K. Hollenberg, G. H. Williams, and A. Thomas Insulin Induces Renal Vasodilation, Increases Plasma Renin Activity, and Sensitizes the Renal Vasculature to Angiotensin Receptor Blockade in Healthy Subjects J. Am. Soc. Nephrol., March 1, 2007; 18(3): 944 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D Stevanovic, D. A Price, M C. Lansang, N. D. Fisher, L. M. Laffel, and N. K Hollenberg Renin Release in Response to Renin System Blockade: Activation of the Renin System in Type 1 Diabetes Mellitus Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2): 78 - 83. [Abstract] [PDF]
|
|
|
|
|
|
P. K. Jacobsen Preventing end stage renal disease in diabetic patients -- genetic aspect (part I) Journal of Renin-Angiotensin-Aldosterone System, March 1, 2005; 6(1): 1 - 14. [Abstract] [PDF]
|
|
|
|
 |
|
 J. A. Miller, J. R. Curtis, and E. B. Sochett Relationship Between Diurnal Blood Pressure, Renal Hemodynamic Function, and the Renin-Angiotensin System in Type 1 Diabetes Diabetes, July 1, 2003; 52(7): 1806 - 1811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D Laverman, D. de Zeeuw, and G. Navis Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy? Journal of Renin-Angiotensin-Aldosterone System, December 1, 2002; 3(4): 205 - 213. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Igarashi, A. Hirata, H. Yamaguchi, H. Tsuchiya, H. Ohnuma, M. Tominaga, M. Daimon, and T. Kato Candesartan Inhibits Carotid Intimal Thickening and Ameliorates Insulin Resistance in Balloon-Injured Diabetic Rats Hypertension, December 1, 2001; 38(6): 1255 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S Gordon, D. A Price, and N. K Hollenberg Blunted suppression of plasma renin activity in diabetes Journal of Renin-Angiotensin-Aldosterone System, September 1, 2000; 1(3): 252 - 256. [Abstract] [PDF]
|
|
|
|
|
|
S. Y. Osei, D. A. Price, L. M. B. Laffel, M. C. Lansang, and N. K. Hollenberg Effect of Angiotensin II Antagonist Eprosartan on Hyperglycemia-Induced Activation of Intrarenal Renin-Angiotensin System in Healthy Humans Hypertension, July 1, 2000; 36(1): 122 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. N. Hopkins, S. C. Hunt, X. Jeunemaitre, B. Smith, D. Solorio, N. D.L. Fisher, N. K. Hollenberg, and G. H. Williams Angiotensinogen Genotype Affects Renal and Adrenal Responses to Angiotensin II in Essential Hypertension Circulation, April 23, 2002; 105(16): 1921 - 1927. [Abstract] [Full Text] [PDF]
|
|